Prediction: Natesto Ad Review

NatestoSteve’s breakdown: This is a big deal and if you think this is not going to spark an ad review, you’re on drugs. The stoner kind – not the testosterone kind . . .

TORONTO, Canada: Trimel Pharmaceuticals Corporation announced today that the United States Food and Drug Administration (FDA) has approved Natesto™ (testosterone), formerly CompleoTRT™, the first and only testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Natesto™ is self-administered via a nasal applicator thereby minimizing the risk of secondary exposure to testosterone of women or children.

“In my practice I regularly encounter men demonstrating symptoms of hypogonadism and physicians will increasingly see this as the North American population ages,” said Dr. Jeffrey Rosen, the medical director and founder of Clinical Research of South Florida (CRSA). “For these patients seeking to restore their testosterone levels, Natesto™ will offer an alternative delivery system that is safer and more convenient than the other options currently available on the market.”

It is conservatively estimated that nearly 13 million American men may have low testosterone levels.  Current treatment guidelines focus on the restoration of the physiological testosterone level through the use of exogenous testosterone preparations, which include topical gels applied by the hands, subcutaneous pellets, transdermal patches, intramuscular injections, oral tablets, as well as a buccal patch.

“The FDA approval for Natesto™ is a major achievement for our company, as it validates our clinical research and development efforts, as well as reinforces our commitment to provide innovative treatment options for patients,” saidTom Rossi, Trimel Pharmaceuticals Corporation President and CEO. “Men suffering from “Low T” will now have a different option to raise their testosterone levels.  This novel route of administration will enable men to take this therapy in mere seconds, without worrying about the risk associated with transferring the product to women or children.  We are now focused on getting Natesto™ to market as expeditiously as possible so that appropriate patients can have access to it.”

About Male Hypogonadism

Male hypogonadism, or low testosterone, is a condition in which the testicles, hypothalamus or pituitary gland is affected by disease or damage that results in inhibiting hormone and testosterone secretion. Signs and symptoms associated with male hypogonadism include erectile dysfunction and decreased sexual desire, fatigue and loss of energy, depressed mood, osteoporosis and regression of secondary sexual characteristics.

About Natesto™ (testosterone) Nasal Gel

Natesto™ is an androgen indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.

About Trimel

Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders. For more information, please visit www.trimelpharmaceuticals.com.

Source:

Type and press Enter to search